GIST Treatment Algorithm: Surgery, Targeted Therapy, and Multidisciplinary Care

Primary Treatment

  • Surgery (R0 resection): Goal for localized, resectable GIST. Laparoscopic/robotic approaches when feasible. Avoid tumor rupture.
  • Neoadjuvant imatinib: For large or unresectable tumors to downsize and facilitate R0 resection.

Adjuvant Therapy

  • Imatinib 400 mg daily for 3 years (standard) or 5 years (high-risk: tumor >10 cm, mitotic count >10/5 mm², rupture).
  • Consider extended adjuvant for intermediate/high risk per NCCN/ESMO.

Advanced/Metastatic Disease

Sequential tyrosine kinase inhibitors (TKIs) based on resistance mutations:

  1. 1st line: Imatinib 400 mg (800 mg for KIT exon 9).
  2. 2nd line: Sunitinib.
  3. 3rd line: Regorafenib.
  4. 4th line: Ripretinib (broad KIT/PDGFRA inhibition) or avapritinib (PDGFRA D842V).

Radiation Therapy

Limited role: palliative for symptomatic bone/brain mets; rarely adjuvant for positive margins when re-resection not feasible.

Monitoring

  • CT abdomen/pelvis every 3–6 months on TKI.
  • FDG-PET for early response assessment (metabolic response precedes size change).
  • Molecular profiling at progression to guide next-line TKI selection.

Multidisciplinary Team

Sarcoma-experienced surgeons, medical oncologists, radiologists, pathologists, and genetic counselors optimize outcomes in this rare malignancy.

Medical Conditions - Related Articles